Skip to main content

Table 4 Predictors of receiving bone mineral density (BMD) measurement and predictors of osteoporosis (OP) treatment: Results from logistic regression models for women

From: Bone mineral density measurement and osteoporosis treatment after a fragility fracture in older adults: regional variation and determinants of use in Quebec

 

BMD testing

OP Treatment

Covariates

Crude OR

Adjusted OR (95% CI)

Crude OR

Adjusted OR (95% CI)

Age in years

    

65–69

1.00

-

1.00

-

70–74

0.71

0.79 (0.70; 0.89) ***

0.89

0.97 (0.85; 0.89 1.10)

75–79

0.42

0.52 (0.46; 0.59) ***

0.70

0.86 (0.76; 0.98) *

≥80

0.11

0.17 (0.15; 0.20) ***

0.40

0.60 (0.53; 0.67)***

Fracture

    

Hip

1.00

-

1.00

-

Humerus

2.14

1.42 (1.26; 1.60)***

1.25

1.00 (0.90; 1.11)

Wrist

3.16

1.83 (1.62; 2.07) ***

1.52

1.18 (1.06; 1.32) *

Vertebral

2.17

2.09 (1.83; 2.38) ***

4.69

4.22 (3.80; 4.69) ***

Social status §

    

At home with no IS

1.00

-

1.00

-

At home with partial IS

0.59

0.73 (0.67; 0.81)***

1.03

1.12 (1.03; 1.21) *

At home with max IS

0.31

0.46 (0.37; 0.56)***

0.76

0.93 (0.81; 1.07)

Living in LTCF

0.02

0.04 (0.02; 0.10)***

-

-

Comorbidity index

0.99

0.98 (0.97; 0.99) ***

1.07

1.02 (1.01; 1.03)***

Prior BMD testing

4.80

2.45 (2.16; 2.79)***

6.19

2.10 (1.82; 2.42)***

Prior OP treatment

2.45

1.51 (1.35; 1.68)***

16.8

13.6 (12.4; 15.0)***

Long-term glucocorticoid use

1.15

0.97 (0.71; 1.31)

3.93

1.45 (1.12; 1.89) *

Distance from BMD device

    

≤ 32 km

1.00

-

-

-

Between 32 and 64 km

0.68

0.75 (0.62; 0.91) *

  

Between 64 and 105 km

0.36

0.36 (0.25; 0.52)***

  

More than 105 km

0.26

0.28 (0.19; 0.40)***

  
  1. * p < 0.05; ** p < 0.001; *** p < 0.0001
  2. § LTCF: Long-term care facility; IS: income supplement